Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
D 15.05 -1.12% -0.17
TGTX closed down 1.12 percent on Monday, March 18, 2024, on 54 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Inside Day Range Contraction -1.12%
Wide Bands Range Expansion -1.12%
Down 3 Days in a Row Weakness -1.12%
Down 4 Days in a Row Weakness -1.12%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
200 DMA Support about 16 hours ago
Down 3% about 19 hours ago
Fell Below 200 DMA about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TG Therapeutics, Inc. Description

TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibodies Monoclonal Antibody Lymphoma Antibody Drug Conjugate Hematological Malignancies Lymphocytes Camidanlumab Tesirine Cd20

Is TGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.67
52 Week Low 6.465
Average Volume 4,925,223
200-Day Moving Average 14.98
50-Day Moving Average 15.93
20-Day Moving Average 15.78
10-Day Moving Average 16.47
Average True Range 0.95
RSI (14) 43.50
ADX 22.64
+DI 23.45
-DI 28.15
Chandelier Exit (Long, 3 ATRs) 16.16
Chandelier Exit (Short, 3 ATRs) 15.70
Upper Bollinger Bands 19.47
Lower Bollinger Band 12.09
Percent B (%b) 0.4
BandWidth 46.81
MACD Line 0.07
MACD Signal Line 0.26
MACD Histogram -0.1936
Fundamentals Value
Market Cap 2.28 Billion
Num Shares 151 Million
EPS -0.19
Price-to-Earnings (P/E) Ratio -79.21
Price-to-Sales 11.76
Price-to-Book 13.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.22
Resistance 3 (R3) 16.17 15.73 16.03
Resistance 2 (R2) 15.73 15.43 15.76 15.96
Resistance 1 (R1) 15.39 15.25 15.17 15.44 15.89
Pivot Point 14.95 14.95 14.84 14.98 14.95
Support 1 (S1) 14.61 14.65 14.39 14.66 14.21
Support 2 (S2) 14.17 14.47 14.20 14.14
Support 3 (S3) 13.83 14.17 14.08
Support 4 (S4) 13.88